Vertex Pharmaceuticals
VRTX
1,494 hedge funds and large institutions have $97.7B invested in Vertex Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 172 funds opening new positions, 609 increasing their positions, 519 reducing their positions, and 96 closing their positions.
79% more first-time investments, than exits
New positions opened: 172 | Existing positions closed: 96
17% more repeat investments, than reductions
Existing positions increased: 609 | Existing positions reduced: 519
4% more funds holding
Funds holding: 1,439 → 1,494 (+55)
1% more capital invested
Capital invested by funds: $96.9B → $97.7B (+$808M)
7% less call options, than puts
Call options by funds: $718M | Put options by funds: $774M
1.67% less ownership
Funds ownership: 92.69% → 91.02% (-1.7%)
27% less funds holding in top 10
Funds holding in top 10: 41 → 30 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.59B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$920M |
| 3 |
Amundi
Paris,
France
|
+$366M |
| 4 |
Jennison Associates
New York
|
+$354M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$176M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.17B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$975M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$589M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$391M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$347M |
VRTX Hedge Fund Activity: Q1 2024 in Review
1,494 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2024, worth a combined $97.7B — up 0.83% from $96.9B a quarter earlier.
Buyers outnumbered sellers: 172 funds opened new VRTX positions and 96 closed out — a net gain of 76 holders — while 609 added to existing stakes and 519 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.59B. The largest seller was Morgan Stanley, cutting an estimated $1.17B.
- 1,494 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2024, up from 1,439 in Q4 2023.
- Funds reported $97.7B of Vertex Pharmaceuticals stock for Q1 2024, up 0.83% quarter-over-quarter.
- 172 funds opened new Vertex Pharmaceuticals positions in Q1 2024 and 96 closed out, a net change of +76 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2024 was Capital World Investors, an estimated $1.59B added.
- The largest Vertex Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $1.17B sold.
Based on aggregated 13F filings for Q1 2024.